ISSN: 1462-8732

Journal Home

Journal Guideline

Journal of Commercial Biotechnology Q4 Unclaimed

Australia

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Journal of Commercial Biotechnology is a journal indexed in SJR in Biotechnology and Economics and Econometrics with an H index of 19. It has a price of 2786 €. It has an SJR impact factor of 0,203 and it has a best quartile of Q4. It is published in English. It has an SJR impact factor of 0,203.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Biotechnology (Q4) Economics and Econometrics (Q4) Management of Technology and Innovation (Q4)

Price

2786 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

0,203

SJR Impact factor

19

H Index

150

Total Docs (Last Year)

220

Total Docs (3 years)

5082

Total Refs

243

Total Cites (3 years)

218

Citable Docs (3 years)

1.19

Cites/Doc (2 years)

33.88

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Advanced Biomedical Engineering Q4
Gene Reports Q4
Microbiology Australia Q4
Series on Biomechanics Q4
Polish Journal of Chemical Technology Q4

Compare this journals

Aims and Scope

Best articles by citations

Monoclonal antibody therapeutics: Leading companies to maximise sales and market share

The growing importance of incorporating US payers into biotechnology drug development decision-making

Singapore -Home base for expansion in Asia

US Supreme Court's Decision on the Patent Ineligibility of Human Genes - BRCA1/BRCA2 as Products of Nature

Exploring technology agglomeration patterns for multinational pharmaceutical and biotechnology firms

Cloning an industry: Strategy typologies of Shanghai biotechnology companies

Practical approaches to early stage life sciences technology valuations

FDA at BIO 2011 -Weighing a hefty mission: Where is the balance?

Globalising clinical development in Japan

Multiyear patterns regarding the relative availability of venture capital for the US biotechnology industry

Chronicling the development of myozyme: The Cure and Chasing Miracles

Traditional ecological knowledge: Impact on commercial health

SHOW MORE ARTICLES

Constructing a processual model of communication in new product development from a multiple case study of biotechnology SMEs

Measuring performance of field-medical programmes: Medical science liaison metrics consensus

Can compliance help marketing and business development?

International Trade and Policies for Genetically Modified Products

Genetic Glass Ceilings: Transgenics for Crop Biodiversity

Building a conducive environment for life science-based entrepreneurship and industry clusters

The Regulatory Challenge of Biotechnology

Editorial

ATMP in practice: Towards a new industry landscape in tissue engineering

Industrial enzymes in bioindustrial sector development: An Indian perspective

Is anyone listening?

Creating bioentrepreneurs: How graduate student organisations foster science entrepreneurship